5 assets in Mismatch Repair Cancer Syndrome

Therapeutic assets addressing Mismatch Repair Cancer Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Mismatch Repair Cancer Syndrome	ImmunoVaccine Technologies, Inc. (IMV Inc.)	P2	B (60)
Cyclophosphamide Mismatch Repair Cancer Syndrome	ImmunoVaccine Technologies, Inc. (IMV Inc.)	P2	CCC (53)
Dpx-Survivac Mismatch Repair Cancer Syndrome	ImmunoVaccine Technologies, Inc. (IMV Inc.)	P2	CCC (53)
Ipilimumab Mismatch Repair Cancer Syndrome	Incyte Corporation	P1	CC (43)
Incb099280 Mismatch Repair Cancer Syndrome	Incyte Corporation	P1	C (32)